Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 19, 2018. The document serves as a transaction notification regarding a lapse of share options for a Person Discharging Managerial Responsibilities (PDMR).
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity figures. This report is strictly a regulatory disclosure of a specific equity transaction and does not contain financial performance data.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details a single event: the lapse of unexercised stock options.
Transaction Details and Management Commentary
- Individual: Mr. N Hirons, SVP, Global Ethics & Compliance.
- Instrument: GlaxoSmithKline plc American Depositary Shares (ADSs), ISIN: US37733W1053.
- Event: Lapse of options granted on February 19, 2008, under the GlaxoSmithKline Share Option Plan.
- Option Price: $44.75 per ADS.
- Volume: Total of 4,600 ADSs lapsed (2,366 Incentive Stock Options and 2,234 Non-Qualified Stock Options).
- Date: February 19, 2018.
Investor Verification Checklist
- Verify the total number of outstanding options for Mr. N Hirons following this lapse.
- Confirm the current market price of GSK ADSs relative to the $44.75 strike price to understand the economic impact of the lapse.
- Review the company's annual report (Form 20-F) for comprehensive financial metrics not included in this transaction notification.